

## Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans

**Running Title:** Genetics of glucose and insulin metabolism

Erik Ingelsson<sup>1,2,\*</sup>, Claudia Langenberg<sup>3,\*</sup>, Marie-France Hivert<sup>4,\*</sup>, Inga Prokopenko<sup>5,6</sup>, Valeriya Lyssenko<sup>7</sup>, Josée Dupuis<sup>8</sup>, Reedik Mägi<sup>5,6</sup>, Stephen Sharp<sup>3</sup>, Anne U. Jackson<sup>9</sup>, Themistocles L. Assimes<sup>10</sup>, Peter Shrader<sup>11</sup>, Joshua W. Knowles<sup>10</sup>, Björn Zethelius<sup>2</sup>, Fahim A. Abbasi<sup>10</sup>, Richard N. Bergman<sup>12</sup>, Antje Bergmann<sup>13</sup>, Christian Berne<sup>14</sup>, Michael Boehnke<sup>9</sup>, Lori L. Bonnycastle<sup>15</sup>, Stefan R. Bornstein<sup>16</sup>, Thomas A. Buchanan<sup>12,17</sup>, Suzannah J. Bumpstead<sup>18</sup>, Yvonne Böttcher<sup>19</sup>, Peter Chines<sup>15</sup>, Francis S. Collins<sup>15</sup>, Cyrus C. Cooper<sup>20</sup>, Elaine M. Dennison<sup>20</sup>, Michael R. Erdos<sup>15</sup>, Ele Ferrannini<sup>21</sup>, Caroline S. Fox<sup>22,23</sup>, Jürgen Graessler<sup>16</sup>, Ke Hao<sup>24</sup>, Bo Isomaa<sup>25,26</sup>, Karen A. Jameson<sup>20</sup>, Peter Kovacs<sup>27</sup>, Johanna Kuusisto<sup>28</sup>, Markku Laakso<sup>28</sup>, Claes Ladenvall<sup>7</sup>, Karen L. Mohlke<sup>29</sup>, Mario A. Morken<sup>15</sup>, Narisu Narisu<sup>15</sup>, David M. Nathan<sup>30</sup>, Laura Pascoe<sup>31</sup>, Felicity Payne<sup>32</sup>, John R. Petrie<sup>33</sup>, Avan A. Sayer<sup>20</sup>, Peter Schwarz<sup>16</sup>, Laura J. Scott<sup>9</sup>, Heather M. Stringham<sup>9</sup>, Michael Stumvoll<sup>19</sup>, Amy J. Swift<sup>15</sup>, Ann-Christine Syvänen<sup>14</sup>, Tiinamaija Tuomi<sup>34</sup>, Jaakko Tuomilehto<sup>35,36</sup>, Anke Tönjes<sup>19,37</sup>, Timo T. Valle<sup>36</sup>, Gordon H. Williams<sup>23</sup>, Lars Lind<sup>14</sup>, Inês Barroso<sup>32</sup>, Thomas Quertermous<sup>10</sup>, Mark Walker<sup>31</sup>, Nicholas J. Wareham<sup>3</sup>, James B. Meigs<sup>11,38</sup>, Mark I. McCarthy<sup>5,6</sup>, Leif Groop<sup>7</sup>, Richard M. Watanabe<sup>12,39</sup>, Jose C. Florez<sup>40,41</sup> on behalf of the MAGIC investigators

E. I., C. L., and M-F. H. contributed equally

**1.** Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; **2.** Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; **3.** MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.; **4.** Centre de Recherche Medicale de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada; **5.** Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.; **6.** Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.; **7.** Department of Clinical Sciences, Diabetes & Endocrinology, University Hospital Malmö, Lund University, Malmö, Sweden; **8.** Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA; **9.** Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA; **10.** Department of Medicine, Stanford University School of Medicine, Stanford, California, USA; **11.** General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, USA; **12.** Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; **13.** Health Care Centre of the Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden, Germany; **14.** Department of Medical Sciences, Uppsala University, Uppsala, Sweden; **15.** Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland, USA; **16.** Department of Medicine III, Division Prevention and Care of Diabetes, University of Dresden, Dresden, Germany; **17.** Department of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; **18.** Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK; **19.** Department of Medicine, University of Leipzig, Leipzig, Germany; **20.** MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, UK; **21.** Department

of Internal Medicine, University of Pisa, Pisa, Italy; **22.** National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA ; **23.** Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; **24.** Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc., Seattle, Washington, USA; **25.** Folkhalsan Research Centre, Helsinki, Finland; **26.** Malmska Municipal Health Care Center and Hospital, Jakobstad, Finland; **27.** Interdisciplinary Centre for Clinical Research, University of Leipzig, Leipzig, Germany; **28.** Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland; **29.** Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; **30.** Diabetes Research Center (Diabetes Unit) and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; **31.** Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; **32.** Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK; **33.** BHF Cardiovascular Research Centre, University of Glasgow, UK; **34.** Department of Medicine, Helsinki University Central Hospital, and Research Program of Molecular Medicine, University of Helsinki, Helsinki, Finland; **35.** Hjelt Institute, Department of Public Health, University of Helsinki and National Institute for Health and Welfare, Unit of Diabetes Prevention, Helsinki, Finland; **36.** South Ostrobothnia Central Hospital, Seinajoki, Finland; **37.** Coordination Centre for Clinical Trials, University of Leipzig, Leipzig, Germany; **38.** Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; **39.** Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; **40.** Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA; **41.** Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.

#### **Corresponding Authors:**

**Erik Ingelsson**

E-mail: erik.ingelsson@ki.se

**Leif Groop**

E-mail: Leif.Groop@med.lu.se

**Richard M. Watanabe**

E-mail: rwatanab@usc.edu

**Jose C. Florez**

E-mail: jcflorez@partners.org

Additional information for this article can be found in an online appendix at <http://diabetes.diabetesjournals.org>

Submitted 26 October 2009 and accepted 18 February 2010.

This is an uncopyedited electronic version of an article accepted for publication in *Diabetes*. The American Diabetes Association, publisher of *Diabetes*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes* in print and online at <http://diabetes.diabetesjournals.org>.

*Objective:* Recent genome-wide association studies have revealed loci associated with glucose and insulin-related traits. We aimed to characterize 19 such loci using detailed measures of insulin processing, secretion and sensitivity to help elucidate their role in regulation of glucose control, insulin secretion and/or action.

*Research Design and Methods:* We investigated associations of loci identified by the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) with circulating proinsulin, measures of insulin secretion and sensitivity from oral glucose tolerance tests (OGTT), euglycemic clamps, insulin suppression tests or frequently-sampled intravenous glucose tolerance tests in non-diabetic humans (n=29,084).

*Results:* The glucose-raising allele in *MADD* was associated with abnormal insulin processing (a dramatic effect on higher proinsulin levels, but no association with insulinogenic index), at extremely persuasive levels of statistical significance ( $P=2.1\times 10^{-71}$ ). Defects in insulin-processing and insulin secretion were seen in glucose-raising allele carriers at *TCF7L2*, *SCL30A8*, *GIPR*, and *FAM148B*. Abnormalities in early insulin secretion were suggested in glucose-raising allele carriers at *MTNR1B*, *GCK*, *FADS1*, *DGKB* and *PROX1* (lower insulinogenic index; no association with proinsulin or insulin sensitivity). Two loci previously associated with fasting insulin (*GCKR* and *IGF1*) were associated with OGTT-derived insulin sensitivity indices in a consistent direction.

*Conclusions:* Genetic loci identified through their effect on hyperglycemia and/or hyperinsulinemia demonstrate considerable heterogeneity in associations with measures of insulin processing, secretion and sensitivity. Our findings emphasize the importance of detailed physiological characterization of such loci for improved understanding of pathways associated with alterations in glucose homeostasis and eventually type 2 diabetes.

A recent meta-analysis of genome-wide association studies of fasting glycemic traits in non-diabetic individuals conducted by the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) has reported the discovery of nine new loci associated with fasting glucose (FG; in or near *ADCY5*, *MADD*, *ADRA2A*, *CRY2*, *FADS1*, *PROX1*, *SLC2A2*, *GLIS3* and *FAM148B*) and one locus associated with fasting insulin levels (*IGF1*) (1). The same study showed effects on FG for seven previously published glucose and/or type 2 diabetes (T2D) loci *G6PC2*, *MTNR1B*, *GCK*, *DGKB*, *GCKR*, *SLC30A8* and *TCF7L2*. Another recent MAGIC meta-analysis, published back-to-back with the aforementioned study, identified two additional novel loci (*GIPR* and *VPS13C*) associated with 2-h glucose after an oral glucose tolerance test (OGTT) (2). In complementary case-control analyses, an increased risk of T2D was demonstrated at genome-wide significance for carriers of the glucose-raising risk alleles in or near the new glycemic loci *ADCY5*, *PROX1*, *GCK*, *DGKB*, *GCKR*, as well as the known T2D loci *MTNR1B*, *SLC30A8* and *TCF7L2* (1). This is a powerful demonstration of how analyses of continuous metabolic traits in healthy individuals can lead to the discovery of previously unsuspected T2D susceptibility genes. Detailed physiological characterization of each locus may help elucidate their role in regulation of glucose levels, insulin secretion and/or action, and identify potential pathways involved in T2D pathogenesis.

The insulin-processing pathway follows several canonical steps in the synthesis and secretion of peptide hormones. Proinsulin is produced in the endoplasmic reticulum, and packaged into secretory vesicles in the Golgi apparatus. Several proteases cleave proinsulin

into mature insulin and C-peptide. In normoglycemic individuals, higher intact proinsulin levels are associated with elevated glucose levels (3; 4), increased insulin secretion and insulin resistance, and in prospective studies higher intact proinsulin has been positively associated with an increased risk of T2D (5). Circulating proinsulin can thus be considered as a measure of  $\beta$ -cell mass or function, insulin processing, insulin secretion, or a combination of these.

Impaired insulin secretion and hepatic and peripheral insulin resistance contribute to the pathogenesis of T2D (6). Glucose-stimulated insulin secretion can be assessed using the insulinogenic index, which is derived from an OGTT and is strongly correlated with more sophisticated measures of insulin secretion (7). The euglycemic-hyperinsulinemic clamp technique, the insulin suppression test, and the frequently-sampled intravenous glucose tolerance test (FSIGT) provide accurate measures of insulin sensitivity, but are difficult to implement in the context of large-scale epidemiological studies. Several indices derived from multiple-point OGTT data correlate well with clamp-assessed sensitivity and have been suggested as more practical surrogate measures (8-11).

Genetic loci associated with glycemic traits have modest effect sizes (1; 2), suggesting that individual studies are likely to be underpowered to detect associations with detailed physiologic characteristics. We therefore established a consortium of 14 studies with detailed measures of circulating proinsulin (nine studies), glucose and insulin at a minimum of three time points during a standard 75g OGTT (nine studies), FSIGT (one study), insulin suppression test (one study) and/or euglycemic-hyperinsulinemic

clamps (two studies). We sought to investigate systematically the effects of single nucleotide polymorphisms (SNPs) previously associated with FG, fasting insulin and/or 2-h glucose in or near the loci listed above on dynamic physiologic measures of insulin processing, secretion and sensitivity, in order to provide insights on how these variants influence glucose levels, and in some cases, increase T2D risk.

## RESEARCH DESIGN AND METHODS

**Cohort Descriptions.** The cohorts included in this study contributed a total of 29,084 unique individuals (Supplementary Table 1). All participants were white adults from Europe or the United States, and free of diabetes assessed by clinical diagnosis, diabetes treatment or  $FG \geq 7$  mmol/L. As in our previous discovery datasets (1; 2), we decided to retain individuals with impaired fasting glucose or impaired glucose tolerance because we wished to avoid truncating the glucose distribution at such low levels that it would effectively eliminate individuals with the greatest genetic predisposition to hyperglycemia, i.e. the most informative segment of the population. Local research ethic committees approved all 14 studies and all participants gave informed consent.

**Phenotype Descriptions.** We studied the following glycemic phenotypes: 1) circulating levels of fasting intact proinsulin (adjusted for fasting insulin), as a reflection of insulin processing, insulin secretion,  $\beta$ -cell mass/function, or a combination thereof ( $n=17,402$ ); 2) the insulinogenic index, defined as  $[(\text{insulin at 30 min}) - (\text{insulin at 0 min})] / [(\text{glucose at 30 min}) - (\text{glucose at 0 min})]$ , as a measure of glucose-stimulated insulin secretion ( $n=15,399$ ) and also indicative of  $\beta$ -cell mass/function (12); 3) insulin sensitivity measured with standard

intravenous methods (M/I derived from euglycemic hyperinsulinemic clamp [ $n=2,250$ ] (13),  $S_I$  from the frequently sampled intravenous glucose tolerance test [FSIGT;  $n=575$ ] (14), and steady-state plasma glucose [SSPG] from the insulin suppression test [ $n=370$ ] (15)), combined after standardization (z-score transformation, total  $n=3,195$ ); and 4) four OGTT-derived measures of insulin sensitivity, namely the Stumvoll (8), Matsuda (9), Belfiore (10) and Gutt (11) indices (see Supplementary Table 3 for formulae;  $n=15,554-15,999$ ). In secondary analyses, we additionally studied associations with split proinsulin ( $n=3,934$ ) and C-peptide ( $n=7,158$ ).

We confirmed the potential utility of the OGTT-derived insulin sensitivity indices by examining correlations with euglycemic clamp-derived insulin sensitivity (M/I) in non-diabetic participants in the ULSAM and RISC studies (see the Supplementary note in the online appendix which is available at <http://diabetes.diabetesjournals.org>); these ranged from 0.67 to 0.76 in ULSAM and 0.36 to 0.49 in RISC.

**Other Quantitative Trait Measurements.** Glucose was measured in whole blood, plasma or serum or a combination of these. Whole blood glucose levels were corrected to plasma glucose using a correction factor of 1.13. Concentrations of insulin, proinsulin and C-peptide were estimated from plasma or serum as described in Supplementary Table 1 for each of the cohorts.

**Statistical Methods.** We tested associations with quantitative glycemic phenotypes for the lead SNPs reported as most significantly associated within 19 regions identified by the recent MAGIC fasting glucose and insulin and 2-hour glucose meta-analyses (1; 2). Alternative proxy SNPs (showing maximal linkage disequilibrium [LD] with the index SNP in the European CEU HapMap sample) were selected for each locus to allow for

differences in genotyping capacities of various platforms (Supplementary Table 2). In samples where initial genotyping of an index SNP failed, a proxy SNP in strong LD with the original SNP was genotyped, whenever possible. Markers which failed Hardy-Weinberg equilibrium (exact  $P$ -value  $< 1 \times 10^{-6}$  or  $1 \times 10^{-4}$  in studies with genome-wide data, or  $< 0.01$  in direct genotyping studies) were excluded from analyses (see Supplementary Table 1 for details). Call rates for directly genotyped SNPs exceeded 90%; information content  $r^2_{\text{hat}} > 0.3$  for MACH-imputed (16) or proper-info  $> 0.4$  for IMPUTE-inferred (17) SNPs were required for SNP inclusion in analysis. In samples where more than one SNP was genotyped within the same region and the index SNP wasn't available, the proxy SNP with higher call rate and stronger LD was selected.

In addition to diabetes or non-white ethnicity, some studies applied additional exclusion criteria as detailed in Supplementary Table 1. In each cohort, we used naturally log-transformed trait values for fasting proinsulin, insulinogenic index, Stumvoll, Matsuda, Belfiore and Gutt insulin sensitivity indices, fasting split proinsulin and C-peptide, and z-score transformed values for M/I,  $S_I$  and SSPG as the dependent variables in linear regression models that included terms for age, sex, study site (if applicable), geographical covariates (if applicable) and age squared (Framingham only) to assess the association of additively coded genotypes with trait values. Analyses were performed with and without adjustment for body mass index (BMI). Analyses of proinsulin and split proinsulin were additionally adjusted for natural log transformed fasting insulin (pmol/l).

Data were available from 14 independent studies, including three with directly genotyped and imputed genome-wide and 11

with *de novo* genotyping data. Association testing was performed using STATA 10.1 (Stata Corporation, College Station, USA) or SAS 9 (SAS Institute Inc., Cary) software for directly genotyped SNPs and using SNPTEST (17) or MERLIN (18) software that takes genotype and imputation uncertainty into account, except in the Framingham Heart Study, where both genotyped and imputed SNPs were analyzed using the lmeKin function from the R kinship package (R Foundation for Statistical Computing, Vienna, Austria, 2007) to account for familial correlation. We performed inverse variance fixed effects meta-analyses using METAL (<http://www.sph.umich.edu/csg/abecasis/Metal/index.html>) and GWAMA (<http://www.well.ox.ac.uk/gwama/index.shtml>) software. Heterogeneity was assessed using the Q-statistics.

We report nominal  $P$ -values without adjustment for multiple testing given the high prior probabilities for associations with the examined phenotypes (all loci have already been associated with at least one glycemic phenotype at genome-wide levels of statistical significance [ $P < 5 \times 10^{-8}$ ]). However, we have focused specifically on the results with  $P$ -values less than  $10^{-3}$ .

## RESULTS

Based on results observed for the different traits, we organized loci displaying similar patterns into groups based on the presumed mechanism of action in the Table (age- and sex-adjusted) and Supplementary Table 5 (additional BMI adjustment). The influence of BMI adjustment on genetic associations was generally minor, and specifically noted when relevant.

### Loci Implicated in Abnormal Insulin Processing

Failing  $\beta$ -cells are expected to show diminished insulin secretion, while compensatory increases in circulating

proinsulin denote the  $\beta$ -cell's attempt to maintain euglycemia (19). Therefore, genetic differences in fasting proinsulin levels (adjusted for fasting insulin) without a concomitant effect on insulinogenic index suggest abnormal insulin processing. The most striking association occurred between the FG-raising allele at *MADD* rs7944584 and higher fasting proinsulin levels ( $P=2.1\times 10^{-71}$ ); its lack of association with the insulinogenic index suggests an effect of this locus on insulin processing (Supplementary Figure 1 and 2). Less significant effects of this allele on lower OGTT-derived insulin sensitivity measures ( $P=0.01-0.03$ ) were also observed. Consistent with the above, *MADD* rs7944584 was strongly associated with higher fasting split proinsulin (Supplementary Table 6), but not with fasting C-peptide (Supplementary Table 7). The 2-h glucose raising allele at *VPS13C* rs17271305 was modestly associated with lower fasting proinsulin levels ( $P=0.02$ ), but not associated with measures of insulin secretion or action.

**Loci Associated with Higher Proinsulin and Lower Insulin Secretion.** Several genetic variants were associated with indices of  $\beta$ -cell dysfunction, i.e. higher fasting proinsulin levels and a lower insulinogenic index: these included the glucose-raising alleles at *TCF7L2* rs7903146 ( $P=4.1\times 10^{-12}$  and  $2.0\times 10^{-7}$  respectively), *SLC30A8* rs13266634 ( $P=2.7\times 10^{-6}$  and 0.0012) and *GIPR* rs10423928 ( $P=6.2\times 10^{-7}$  and  $2.1\times 10^{-13}$ ). A trend was also seen for the FG-raising allele at *FAM148B* rs11071657 associating with higher fasting proinsulin levels ( $P=0.004$ ) and lower insulinogenic index ( $P=0.06$ ). At these loci the relationship between the insulinogenic index and fasting proinsulin levels was linear for carriers of the protective allele, whereas carriers of the risk alleles failed to demonstrate an increase in insulinogenic index in proportion to rising proinsulin levels (Figure 1a-d). Except for an

association between the *GIPR* rs10423928 and higher insulin sensitivity as assessed by the Belfiore ( $P=1.0\times 10^{-8}$ ), Matsuda ( $P=0.0008$ ) and Stumvoll ( $P=0.003$ ) indices, the other associations of these SNPs with measures of insulin sensitivity were very modest ( $P=0.01-0.05$ ) and/or inconsistent. *TCF7L2* rs7903146 was the only locus in this group associated with lower C-peptide levels (Supplementary Table 7). We note that although the *VPS13C* and *FAM148B* loci are physically close to each other (101 kb apart), LD between the two index SNPs is relatively weak ( $r^2=0.28$  based on HapMap CEU).

**Loci Associated with Abnormalities in Early Insulin Secretion.** A subset of other variants showed association between FG-raising alleles and lower insulinogenic index without an association with fasting proinsulin levels: *MTNR1B* rs10830963 ( $P=2.3\times 10^{-19}$ ), *GCK* rs4607517 ( $P=2.2\times 10^{-4}$ ), *FADS1* rs174550 ( $P=0.001$ ), *DGKB* rs2191349 ( $P=0.006$ ) and *PROX1* rs340874 ( $P=0.02$ ). The FG-raising alleles at *GCK* ( $P=8.1\times 10^{-5}$ ) and *MTNR1B* ( $P=0.006$ ) were also associated with a lower Gutt index, but not with any of the other insulin sensitivity measures.

The FG-raising allele at *G6PC2* rs560887 was associated with a higher insulinogenic index ( $P=5.0\times 10^{-5}$ ), a finding previously reported by others (20). It was also weakly associated with lower insulin sensitivity measured by intravenous techniques in BMI-adjusted analyses ( $P=0.02$ ; Supplementary Table 5).

**Loci Associated with Reduced Insulin Sensitivity.** The FG-raising allele at *GCKR* rs780094 was associated with lower insulin sensitivity by the Stumvoll ( $P=0.001$ ), Matsuda ( $P=2.9\times 10^{-5}$ ) and Belfiore ( $P=0.003$ ) indices, whereas the fasting insulin-raising allele at *IGF1* rs35767 was associated with lower insulin sensitivity by the Matsuda ( $P=0.01$ ), Belfiore ( $P=0.02$ ) and Gutt ( $P=0.002$ ) indices. *GCKR* rs780094 was also

associated with increased C-peptide levels (Supplementary Table 7).

**Loci without Obvious Effects on Insulin Processing, Secretion or Sensitivity.** Five of the examined loci, *ADCY5* rs11708067, *ADRA2A* rs10885122, *CRY2* rs11605924, *SLC2A2* rs11920090, and *GLIS3* rs7034200, did not show any apparent associations with any of the examined phenotypes (Table). We note that the *ADRA2A* SNP rs10885122, previously associated with fasting glucose (1) and assayed here, is 202 kb away from and uncorrelated with rs553668 ( $r^2=0.003$  in HapMap CEU). The A allele at rs553668 has been recently associated with T2D and reduced insulin secretion in a Scandinavian population (21). In our MAGIC meta-analysis of ~14,000 individuals, the A allele at rs553668 is nominally associated with higher  $\beta$ -cell function by homeostasis model assessment ( $P=0.003$ ) and higher fasting insulin ( $P=0.02$ ), but shows no association with fasting glucose ( $P=0.21$ ).

## DISCUSSION

In this report we investigated the effects of 19 SNPs previously associated with FG, fasting insulin and/or 2-h glucose on multiple physiologic measures of insulin processing, secretion and sensitivity in 14 cohorts with over 29,000 unique participants. For at least 12 of these SNPs, this is the first report to study their associations with such comprehensive physiologic measures of insulin and glucose metabolism. Our results demonstrate that these genetic loci influence glycemic regulation by diverse pathways (Supplementary Figure 3).

**Loci Implicated in Abnormal Insulin Processing.** The glucose-raising allele at *MADD* was associated with elevated fasting proinsulin (adjusted for fasting insulin), but *not* with insulin secretion. The dramatic effect size on fasting proinsulin levels (two- to ten-fold that of other loci) seems out of

proportion with its modest elevation of FG and an otherwise unremarkable impact on other glycemic measures, suggesting that this locus is associated with an isolated insulin processing defect without a major impairment of insulin secretory capacity. It is therefore not surprising that despite the effects of this locus on FG and fasting proinsulin levels, it has a negligible influence on T2D risk (1). *MADD* encodes a death domain-containing adaptor protein, which interacts with the death domain of TNF- $\alpha$  receptor 1 and propagates apoptotic signals (22); however, if functional variants in *MADD* were involved in mechanisms leading to  $\beta$ -cell damage, one would expect to have seen a concomitant deterioration of  $\beta$ -cell function. The isolated proinsulin association raises the possibility that other genes in the region may contain a causal variant (in LD with rs7944584) which is functionally responsible for the observed insulin processing defect: among them, *PACSIN3* encodes a protein involved in vesicle formation, transport and endocytosis whose transcript is relatively abundant in human pancreas (23), *ARFGAP2* has been implicated in vesicular trafficking between the Golgi and the endoplasmic reticulum (24), and *SLC39A13* encodes a zinc transporter (25).

**Loci Associated with Higher Proinsulin and Lower Insulin Secretion.** The glucose-raising variants at *TCF7L2*, *SLC30A8*, *GIPR* and *FAM148B* were all associated with increased fasting proinsulin levels and decreased insulinogenic index. The relationship between the insulinogenic index and fasting proinsulin was linear for carriers of the protective allele at *TCF7L2* and *SLC30A8*, whereas carriers of the risk alleles failed to demonstrate an increase in insulinogenic index in proportion to rising proinsulin levels, indicating an active secretion of insulin precursors in lieu of mature insulin. This has several potential



explanations: reduced  $\beta$ -cell mass, through either diminished proliferation or enhanced apoptosis, resulting in increased  $\beta$ -cell stress in the face of increased insulin demand; an impairment in the molecular processing from proinsulin to insulin; or defective vesicle trafficking. In sum, all these possibilities could manifest themselves by the exocytosis of more pre-protein products and lower secretion of insulin in response to glucose.

*TCF7L2* encodes a nuclear receptor for  $\beta$ -catenin involved in the Wnt signaling pathway; the association of SNP rs7903146 in this gene with T2D is now well established as the strongest genetic determinant of T2D yet described. Here we confirm the previously reported associations of this variant with measures of impaired insulin secretion and with fasting proinsulin levels (see (26) for review). Current evidence suggests that *TCF7L2* causes an impairment in insulin secretion by affecting insulin granule exocytosis and  $\beta$ -cell responsiveness to incretins (perhaps by downregulation of glucagon-like peptide 1 [GLP-1] receptors); incretin resistance may in turn diminish  $\beta$ -cell mass. Our data support any of the above mechanisms.

*GIPR* encodes the receptor for glucose-dependent insulinotropic polypeptide (GIP, also known as *gastric inhibitory polypeptide*), another incretin hormone. Interaction of GIP with its receptor on the  $\beta$  cells increases cAMP levels and intracellular calcium, which enhances exocytosis of insulin-containing granules, mostly during the later response to oral glucose (20-120 minutes) (27). Individuals with T2D and their relatives have an impaired insulinotropic effect of GIP (28), perhaps due to defective or reduced number of GIP receptors in  $\beta$  cells (29). A common variant in *GIPR* was associated with 2-h glucose in a prior MAGIC meta-analysis (2), as well as a lower insulinogenic index and a lower ratio of insulin to glucose area under

the curve during an OGTT; in this study we have replicated the insulinogenic index result and shown an association of the same allele with higher fasting proinsulin levels. The effect of this variant on reducing both early and late insulin secretion may explain the perceived improvement in insulin sensitivity by OGTT-derived measures, which is driven by lower insulin levels throughout the OGTT. These observations are fully consistent with the known mechanisms described above.

*SLC30A8* encodes the zinc transporter ZnT-8, which co-localizes with insulin in the  $\beta$  cell and is important in the storage and maturation of insulin within cytoplasmic granules (30). ZnT8-null mice have impaired glucose tolerance and decreased insulin secretion *in vivo* (31). Furthermore, mice carrying a *Slc30a8* exon 3 deletion had lower plasma insulin levels, and islets from these mice showed decreased zinc content and lower glucose-stimulated insulin secretion (32). Here, we confirm previous reports that carriers of the risk genotype at *SLC30A8* exhibit abnormalities in insulin secretion (33) and increased circulating proinsulin (34). Thus variants in both *TCF7L2* and *SLC30A8* affect FG, proinsulin levels and insulin secretion, and in doing so increase T2D risk.

We provided biologic mechanisms to explain the associations we observed between variation in these loci and abnormal insulin processing or elevated proinsulin levels. However, many different biologic conditions can result in abnormal insulin processing and regulation of proinsulin levels. Therefore, in the absence of experiments to directly test these mechanisms, we view these associations as hypothesis-generating for future studies to formally test these mechanisms.

**Loci Associated with Abnormalities in Early Insulin Secretion.** Genetic defects in pathways primarily involved in insulin secretion are expected to cause higher glucose levels. Of all examined loci, the glucose-

raising alleles of SNPs at *MTNR1B*, *FADS1* and *DGKB* and *GCK* showed an association with lower insulinogenic index, but no significant association with fasting proinsulin or insulin sensitivity. Thus, these loci seem to influence insulin secretory capacity without affecting insulin processing or inducing significant  $\beta$ -cell stress, which would result in higher circulating proinsulin.

Our results confirm that the glucose-raising allele in *MTNR1B* (encoding the melatonin receptor 1B) is associated with lower insulin secretion after oral or intravenous glucose challenge (35-37). We did not see a significant association of *MTNR1B* with fasting proinsulin levels, which is in line with the observation in the Tübingen Family Study (37), but in contrast with the Helsinki Birth Cohort results (36). *MTNR1B* is expressed in human islets and co-localizes with insulin; melatonin inhibits insulin secretion by rat insulinoma cells (36; 37). It is therefore possible that genetic variation in *MTNR1B* enhances  $\beta$ -cell responsiveness to melatonin.

Fatty acid metabolism may also play a role in early insulin secretion. *FADS1* encodes fatty acid desaturase 1, a key enzyme in the metabolism of unsaturated (omega-3 and omega-6) fatty acids. These lipid moieties play a major role in the stability of cellular membranes, but fatty acid desaturases can also convert polyunsaturated fatty acids into cell signaling metabolites. Polymorphisms in *FADS1* that are strongly correlated with the FG-associated SNP have been associated with *FADS1* mRNA expression levels in liver (1) and differences in cell membrane or circulating fatty acid profiles (38; 39). The type of fatty acids influences glucose-stimulated insulin secretion in incubated pancreatic islet (40) and in perfused pancreas (41). Insulin secretion differs in response to oral challenges varying in their fatty acid composition (42; 43). Thus, a plausible

mechanism by which insulin secretory function is reduced without the need to postulate reduced  $\beta$ -cell mass or survival can also be envisioned for this locus.

*DGKB* encodes for diacylglycerol kinase  $\beta$ , which is a member of a family of intracellular lipid kinases that phosphorylate diacylglycerols. Within the  $\beta$  cell, diacylglycerols are implicated in the intracellular pathways of parasympathetic stimulation of insulin secretion, which is activated by meal intake through the vagal nerve (44). If a *DGKB* variant influences the  $\beta$ -cell response to neural stimulation via a second messenger pathway, it can also do so without affecting  $\beta$ -cell integrity and thus show no association with fasting proinsulin levels.

*GCK* encodes glucokinase, which phosphorylates glucose to glucose-6-phosphate and is thus the rate-limiting enzyme for glucose sensing in  $\beta$  cells. Loss-of-function mutations in *GCK* are responsible for maturity-onset diabetes of the young (MODY) 2, a syndrome characterized by mild fasting hyperglycemia and glucose intolerance due to reduced sensitivity of insulin secretion to changes in glycemia, resulting in an impaired secretory response (45). Non-MODY *GCK* variants have been associated with FG levels in multiple cohorts (46), an association that reached genome-wide significance in MAGIC (35).

The *G6PC2* FG-raising allele was associated with a *higher* insulinogenic index; this is consistent with observations in obese children, where another SNP in the same locus was associated with both increased FG and higher insulinogenic index (47), and in Mexican Americans, where the FG-raising allele was also associated with increased FG and OGTT 30- minute insulin change (48). *G6PC2* encodes glucose-6-phosphatase, catalytic 2, which catalyzes glucose-6-phosphate dephosphorylation, thereby

opposing the action of GCK in the  $\beta$  cell. The observation that risk allele carriers have a higher FG and yet a higher insulinogenic index is in contrast with the results obtained for *GCK*, and may explain why this variant shows a flat-to-slightly protective effect on T2D (1). Thus, a simple elevation of the glucostatic set point does not provide a fully satisfactory explanation. An alternative is that balance between GCK and G6PC2 activities may be affected by genetic variation resulting in changes in pulsatile insulin secretion, which could interfere with normal insulin signaling between the pancreas and insulin-sensitive tissues. This hypothesis is supported by two lines of evidence. First, GCK and G6PC2 regulate the rate-limiting step of glycolysis and oscillations in glycolysis have been shown to be correlated with oscillations in insulin secretion *in vitro* (49; 50). Second, recent animal studies showing that disruption of pulsatile insulin secretion results in a loss of efficiency in insulin action at the liver, leading to modest hepatic insulin resistance and increased hepatic glucose output (51); these changes would then cause the observed compensatory rise in insulin secretion.

**Loci Associated with Insulin Resistance.** FG-raising alleles at *GCKR* and *IGF1* have previously been shown to be associated with insulin resistance by homeostasis model assessment (1). In the present study, we confirm this observation using dynamic indices not restricted to glucose and insulin measured in the fasting state. Both *GCKR* and *IGF1* are strongly expressed in the liver, and could thus contribute to development of hepatic insulin resistance. *GCKR* encodes glucokinase regulatory protein, which inhibits glucokinase in liver; the index SNP is in strong LD with the missense variant P446L, whose FG-raising allele inhibits glucokinase activity in the presence of physiological concentrations of fructose-6 phosphate (52), thus leading to increased hepatic glucose

production. *IGF1* encodes the insulin-like growth factor 1 (IGF-1), which has significant structural homology with insulin. Circulating IGF-1 can bind to insulin receptors and stimulate glucose transport in fat and muscle while decreasing hepatic glucose output, thus lowering blood glucose while suppressing insulin secretion (53). However, the role of IGF-1, and especially polymorphisms in or near *IGF1*, in glucose homeostasis and insulin sensitivity is not well understood.

Despite state-of-the art methods and the large sample size to date we found little evidence of the examined SNPs being convincingly associated with insulin sensitivity. This could reflect a smaller sample size for the intravenous insulin sensitivity analyses (n=3,195) than for the analyses of insulin secretion, and hence lower statistical power. It is well established that measures of  $\beta$ -cell function show stronger heritability than measures of insulin action, the latter being subject to large day-to-day variation. While insulin sensitivity measures are correlated, differences among them do exist that increase heterogeneity and reduce power (54). Although the correlation between intravenous and OGTT-derived measures of insulin resistance is high (see Supplementary Table 4), the discrepancy in results among these measures may reflect differences in the genetic contribution to the correlation (55). In addition, biological reasons may explain the lack of associations with insulin sensitivity, including trait heterogeneity (i.e. constructed by multiple components with presumably different genetic determinants, such as hepatic glucose output and peripheral glucose uptake), or selection bias, since these SNPs were chosen from analyses of FG, fasting insulin and 2-h glucose, traits that might be more strongly associated with insulin processing and secretion than with peripheral insulin sensitivity. Regardless, these results suggest that care must be exerted when

comparing association results that use differing measures of insulin sensitivity, and highlight that their underlying genetic physiology requires further study.

**Limitations.** Because our studies are conducted in free-living humans, our mechanistic inferences are limited by the measures one can derive from human subjects *in vivo* and the assumptions contained therein. In the absence of appropriate cellular or animal models, we cannot offer conclusive proof of mechanism at the molecular level. Furthermore, a strong association with one specific measure does not preclude a weaker association with a different measure, and therefore a complex interplay between various processes involved in insulin secretion and action may be operational. Glucose itself (even in the non-diabetic range studied here) may affect the variables under consideration; however, because these variants were discovered by their association with glucose levels, it did not seem advisable to remove the

contribution of glucose to the traits under study by statistical adjustment. Finally, we emphasize that the SNPs genotyped here are simply associated with the traits under consideration, and thus may be correlated with but not represent the causal variants, nor lie in the biologically relevant genes.

## CONCLUSION

We have undertaken a detailed physiologic characterization of 19 genetic loci recently identified through associations with fasting glucose or insulin and/or 2-h glucose, and demonstrate considerable heterogeneity in associations of these loci with measures of insulin processing, secretion and sensitivity. Our findings emphasize the importance of detailed physiological characterization of such loci for improved understanding of mechanisms by which newly discovered loci might influence glucose physiology and T2D risk.

## REFERENCES

1. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JRB, Egan JM, Lajunen T, Grarup N, Sparsø T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccascocca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen Y, Chines P, Clarke R, Coin LJM, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day INM, de Geus E, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen A, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PRV, Jørgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Bacquer OL, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orrù M, Pakyz R, Palmer CNA, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurdsson G, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvänen A, Tanaka T, Thorand B, Tichet J, Tönjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JCM, Yarnell JWG, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, DIAGRAM C, GIANT C, Global BPGen C, Borecki IB, Loos RJJ, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Ríos M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Hamsten A, on behalf of Procardis Consortium, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BWJH, Boomsma D, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Du, C.M., Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruukonen A, Jarvelin M, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I: New genetic loci implicated in

- fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* E-pub Jan 17, 2010
2. Saxena R, Hivert M-F, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N: Genetic variation in gastric inhibitory polypeptide receptor (*GIPR*) impacts the glucose and insulin responses to an oral glucose challenge. *Nat Genet* E-pub Jan 17, 2010
  3. Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Groop L: Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia. *Diabetes Care* 17:1307-1310, 1994
  4. Roder ME, Eriksson J, Hartling SG, Groop L, Binder C: Proportional proinsulin responses in first-degree relatives of patients with type 2 diabetes mellitus. *Acta Diabetol* 30:132-137, 1993
  5. Hanley AJ, D'Agostino R, Jr., Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM: Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. *Diabetes* 51:1263-1270, 2002
  6. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia* 46:3-19, 2003
  7. Tura A, Kautzky-Willer A, Pacini G: Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. *Diabetes Res Clin Pract* 72:298-301, 2006
  8. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. *Diabetes Care* 23:295-301, 2000
  9. Matsuda M, DeFronzo R: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 22:1462-1470, 1999
  10. Belfiore F, Iannello S, Volpicelli G: Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. *Mol Genet Metab* 63:134-141, 1998
  11. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB: Validation of the insulin sensitivity index (ISI<sub>0,120</sub>): comparison with other measures. *Diabetes Research and Clinical Practice* 47:177-184, 2000
  12. Byrne CD, Wareham NJ, Brown DC, Clark PM, Cox LJ, Day NE, Palmer CR, Wang TW, Williams DR, Hales CN: Hypertriglyceridemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. *Diabetologia* 37:889-896, 1994
  13. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 237:E214-223, 1979
  14. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. *J Clin Invest* 79:790-800, 1987
  15. Shen SW, Reaven GM, Farquhar JW: Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. *J Clin Invest* 49:2151-2160, 1970
  16. Li Y, Abecasis GR: Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. *Am J Hum Genet* S79:2290, 2006

17. Marchini J, Howie B, Myers S, McVean G, Donnelly P: A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* 39:906-913, 2007
18. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet* 30:97-101, 2002
19. Bell G, Polonsky, KS: Diabetes mellitus and genetically programmed defects in beta-cell function. *Nature* 414:788-791, 2001
20. Rose CS, Grarup N, Krarup NT, Poulsen P, Wegner L, Nielsen T, Banasik K, Faerch K, Andersen G, Albrechtsen A, Borch-Johnsen K, Clausen JO, Jorgensen T, Vaag A, Pedersen O, Hansen T: A variant in the *G6PC2/ABCB11* locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. *Diabetologia*, 2009
21. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ, Nagaraj V, Reinbothe TM, Tuncel J, Eliasson L, Groop L, Rorsman P, Salehi A, Lyssenko V, Luthman H, Renstrom E: Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. *Science* 327:217-220
22. Kurada BR, Li LC, Mulherkar N, Subramanian M, Prasad KV, Prabhakar BS: MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. *J Biol Chem* 284:13533-13541, 2009
23. Sumoy L, Pluvinet R, Andreu N, Estivill X, Escarceller M: PACSIN 3 is a novel SH3 domain cytoplasmic adapter protein of the pacsin-syndapin-FAP52 gene family. *Gene* 262:199-205, 2001
24. Frigerio G, Grimsey N, Dale M, Majoul I, Duden R: Two human ARFGAPs associated with COP-I-coated vesicles. *Traffic* 8:1644-1655, 2007
25. Taylor KM, Nicholson RI: The LZT proteins; the LIV-1 subfamily of zinc transporters. *Biochim Biophys Acta* 1611:16-30, 2003
26. Pearson ER: Translating TCF7L2: from gene to function. *Diabetologia* 52:1227-1230, 2009
27. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *Am J Physiol Endocrinol Metab* 287:E199-206, 2004
28. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegell WH, Nauck MA: Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. *Diabetes* 50:2497-2504, 2001
29. Holst JJ, Gromada J, Nauck MA: The pathogenesis of NIDDM involves a defective expression of the GIP receptor. *Diabetologia* 40:984-986, 1997
30. Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B, Kerr-Conte J, Van Lommel L, Grunwald D, Favier A, Seve M: In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. *J Cell Sci* 119:4199-4206, 2006
31. Nicolson TJ, Bellomo EA, Wijesekara N, Loder MK, Baldwin JM, Gyulkhandanyan AV, Koshkin V, Tarasov AI, Carzaniga R, Kronenberger K, Taneja TK, da Silva Xavier G, Libert S, Froguel P, Scharfmann R, Stetsyuk V, Ravassard P, Parker H, Gribble FM, Reimann F, Sladek R, Hughes SJ, Johnson PRV, Masseboeuf M, Burcelin R, Baldwin SA, Liu M, Lara-Lemus R, Arvan P, Schuit FC, Wheeler MB, Chimienti F, Rutter GA: Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. *Diabetes*:-, 2009

32. Pound LD, Sarkar SA, Benninger RK, Wang Y, Suwanichkul A, Shadoan MK, Printz RL, Oeser JK, Lee CE, Piston DW, McGuinness OP, Hutton JC, Powell DR, O'Brien RM: Deletion of the mouse *Slc30a8* gene encoding zinc transporter-8 results in impaired insulin secretion. *Biochem J* 421:371-376, 2009
33. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorraddottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K: A variant in *CDKALI* influences insulin response and risk of type 2 diabetes. *Nat Genet* 39:770-775, 2007
34. Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschrutter O, Staiger H, Stefan N, Haring HU, Fritsche A: Polymorphisms in the *TCF7L2*, *CDKALI* and *SLC30A8* genes are associated with impaired proinsulin conversion. *Diabetologia* 51:597-601, 2008
35. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, Manning AK, Jackson AU, Aulchenko Y, Potter SC, Erdos MR, Sanna S, Hottenga JJ, Wheeler E, Kaakinen M, Lyssenko V, Chen WM, Ahmadi K, Beckmann JS, Bergman RN, Bochud M, Bonnycastle LL, Buchanan TA, Cao A, Cervino A, Coin L, Collins FS, Crisponi L, de Geus EJ, Dehghan A, Deloukas P, Doney AS, Elliott P, Freimer N, Gateva V, Herder C, Hofman A, Hughes TE, Hunt S, Illig T, Inouye M, Isomaa B, Johnson T, Kong A, Krestyaninova M, Kuusisto J, Laakso M, Lim N, Lindblad U, Lindgren CM, McCann OT, Mohlke KL, Morris AD, Naitza S, Orru M, Palmer CN, Pouta A, Randall J, Rathmann W, Saramies J, Scheet P, Scott LJ, Scuteri A, Sharp S, Sijbrands E, Smit JH, Song K, Steinthorsdottir V, Stringham HM, Tuomi T, Tuomilehto J, Uitterlinden AG, Voight BF, Waterworth D, Wichmann HE, Willemsen G, Witteman JC, Yuan X, Zhao JH, Zeggini E, Schlessinger D, Sandhu M, Boomsma DI, Uda M, Spector TD, Penninx BW, Altshuler D, Vollenweider P, Jarvelin MR, Lakatta E, Waeber G, Fox CS, Peltonen L, Groop LC, Mooser V, Cupples LA, Thorsteinsdottir U, Boehnke M, Barroso I, Van Duijn C, Dupuis J, Watanabe RM, Stefansson K, McCarthy MI, Wareham NJ, Meigs JB, Abecasis GR: Variants in *MTNR1B* influence fasting glucose levels. *Nat Genet* 41:77-81, 2009
36. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spiegel P, Bugliani M, Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, Mulder H, Groop L: Common variant in *MTNR1B* associated with increased risk of type 2 diabetes and impaired early insulin secretion. *Nat Genet* 41:82-88, 2009
37. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, Silbernagel G, Stefan N, Haring HU, Fritsche A: Polymorphisms within the novel type 2 diabetes risk locus *MTNR1B* determine beta-cell function. *PLoS ONE* 3:e3962, 2008
38. Gieger C, Geistlinger L, Altmaier E, Hrabé de Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, Illig T, Suhre K: Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. *PLoS Genet* 4:e1000282, 2008
39. Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, Demmelmair H, Illig T, Koletzko B, Heinrich J: Common genetic variants of the *FADS1 FADS2* gene cluster and their



- reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum. Mol. Genet.* 15:1745-1756, 2006
40. Pareja A, Tinahones FJ, Soriguer FJ, Monzon A, Esteva de Antonio I, Garcia-Arnes J, Oliveira G, Ruiz de Adana MS: Unsaturated fatty acids alter the insulin secretion response of the islets of Langerhans in vitro. *Diabetes Res Clin Pract* 38:143-149, 1997
  41. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD: The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. *J Clin Invest* 100:398-403, 1997
  42. Xiao C, Giacca A, Carpentier A, Lewis GF: Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. *Diabetologia* 49:1371-1379, 2006
  43. Christiansen E, Schnider S, Palmvig B, Tauber-Lassen E, Pedersen O: Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects on postprandial insulinemia and glycemia in obese patients with NIDDM. *Diabetes Care* 20:881-887, 1997
  44. Gilon P, Henquin JC: Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. *Endocr Rev* 22:565-604, 2001
  45. Velho G, Froguel P, Clement K, Pueyo ME, Rakotoambinina B, Zouali H, Passa P, Cohen D, Robert JJ: Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. *Lancet* 340:444-448, 1992
  46. Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S, Lawlor DA, Pembrey ME, Ring S, Wilkin TJ, Voss LD, Jeffery AN, Metcalf B, Ferrucci L, Corsi AM, Murray A, Melzer D, Knight B, Shields B, Smith GD, Hattersley AT, Di Rienzo A, Frayling TM: A common haplotype of the glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. *Am J Hum Genet* 79:991-1001, 2006
  47. Dos Santos C, Bougneres P, Fradin D: A single-nucleotide polymorphism in a methylatable Foxa2 binding site of the G6PC2 promoter is associated with insulin secretion in vivo and increased promoter activity in vitro. *Diabetes* 58:489-492, 2009
  48. Li X, Shu YH, Xiang AH, Trigo E, Kuusisto J, Hartiala J, Swift AJ, Kawakubo M, Stringham HM, Bonnycastle LL, Lawrence JM, Laakso M, Allayee H, Buchanan TA, Watanabe RM: Additive effects of genetic variation in *GCK* and *G6PC2* on insulin secretion and fasting glucose. *Diabetes*, 2009
  49. Chou HF, Berman N, Ipp E: Oscillations of Lactate Released from Islets of Langerhans - Evidence for Oscillatory Glycolysis in Beta-Cells. *American Journal of Physiology* 262:E800-E805, 1992
  50. Deeney JT, Kohler M, Kubik K, Brown G, Schultz V, Tornheim K, Corkey BE, Berggren PO: Glucose-induced metabolic oscillations parallel those of Ca<sup>2+</sup> and insulin release in clonal insulin-secreting cells - A multiwell approach to oscillatory cell behavior. *Journal of Biological Chemistry* 276:36946-36950, 2001
  51. Matveyenko AV, Veldhuis JD, Butler PC: Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. *Diabetes* 55:2347-2356, 2006
  52. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, Gloyn AL: The P446L variant in *GCKR* associated with fasting plasma glucose and triglyceride levels

- exerts its effect through increased glucokinase activity in liver. *Hum Mol Genet* 18:4081-4088, 2009
53. Clemmons DR: Role of insulin-like growth factor in maintaining normal glucose homeostasis. *Horm Res* 62 Suppl 1:77-82, 2004
  54. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. *Endocr Rev* 6:45-86, 1985
  55. Bergman RN, Zaccaro DJ, Watanabe RM, Haffner SM, Saad MF, Norris JM, Wagenknecht LE, Hokanson JE, Rotter JI, Rich SS: Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. *Diabetes* 52:2168-2174, 2003

## Figure Legends

### **Figure 1a-d. Insulin secretion and proinsulin in the RISC study (n=1,319) by genotype at *TCF7L2* rs7903146, *SLC30A8* rs13266634, *GIPR* rs10423928, and *FAM148B* rs11071657**

Proinsulin processing can be studied by plotting the relation between early insulin secretion (measured by insulinogenic index from OGTT) and proinsulin. The three curves in each plot represent the regression lines of the logarithm of estimated insulin secretion as a linear function of the proinsulin level for all participants, distributed according to the genotypes. In all four plots, the relationship between the insulinogenic index and proinsulin levels was linear for carriers of the protective allele, whereas carriers of the risk alleles failed to demonstrate an increase in insulinogenic index in proportion to rising proinsulin levels, indicating the active secretion of insulin precursors in lieu of mature insulin.

**Table. Associations of 19 SNPs previously associated with fasting glucose, fasting insulin and/or 2-h glucose on detailed physiologic measures of insulin processing, secretion and sensitivity**

SNP	Nearest gene	Alleles (effect <sup>†</sup> /other)		Insulin processing, secretion and/or $\beta$ -cell function	Insulin secretion	Insulin sensitivity					
				Proinsulin <sup>†</sup> (n=17,402)	Insulinogenic index <sup>†</sup> (n=15,399)	Insulin sensitivity intravenous measures <sup>‡</sup> (n=3,195)	Stumvoll <sup>§</sup> (n=15,789)	Matsuda <sup>§</sup> (n=15,554)	Belfiore <sup>§</sup> (n=15,802)	Gutt <sup>§</sup> (n=15,999)	
<b>Loci implicated in abnormal insulin processing</b>											
rs7944584	MADD	A/T		Beta (SE)	0.10 (0.0059)	0.0072 (0.01)	-0.024 (0.028)	-0.011 (0.005)	-0.02 (0.0078)	-0.0085 (0.0038)	-0.0076 (0.0048)
				$P_{age+sex}$	$2.07 \times 10^{-71}$	0.47	0.38	0.033	0.0097	0.024	0.11
rs17271305	VPS13C	G/A		Beta (SE)	-0.018 (0.007)	0.019 (0.013)	-0.022 (0.039)	0.0041 (0.0055)	-0.0034 (0.0097)	-0.0011 (0.0047)	-0.0012 (0.0078)
				$P_{age+sex}$	0.016	0.13	0.58	0.46	0.72	0.81	0.88
<b>Loci associated with higher proinsulin and lower insulin secretion</b>											
rs7903146	TCF7L2	T/C		Beta (SE)	0.045 (0.0066)	-0.057 (0.011)	-0.01 (0.026)	0.011 (0.0052)	0.022 (0.0084)	0.011 (0.004)	-0.0052 (0.0057)
				$P_{age+sex}$	$4.08 \times 10^{-12}$	$2.00 \times 10^{-7}$	0.70	0.041	0.0082	0.0053	0.36
rs13266634	SLC30A8	C/T		Beta (SE)	0.031 (0.0067)	-0.035 (0.011)	-0.04 (0.027)	0.0047 (0.0049)	0.013 (0.0083)	0.0072 (0.0038)	-0.003 (0.0057)
				$P_{age+sex}$	$2.74 \times 10^{-6}$	0.0012	0.14	0.34	0.12	0.055	0.6
rs10423928	GIPR	A/T		Beta (SE)	0.031 (0.0062)	-0.079 (0.011)	0.033 (0.032)	0.016 (0.0055)	0.029 (0.0085)	0.025 (0.0044)	-0.0099 (0.0051)
				$P_{age+sex}$	$6.23 \times 10^{-7}$	$2.10 \times 10^{-13}$	0.30	0.0029	0.00077	$1.00 \times 10^{-8}$	0.053
rs11071657	FAM148B	A/G		Beta (SE)	0.017 (0.0059)	-0.019 (0.01)	0.016 (0.028)	-0.0033 (0.0058)	0.0026 (0.0081)	0.0017 (0.0043)	-0.0001 (0.0049)
				$P_{age+sex}$	0.0037	0.063	0.56	0.56	0.74	0.70	0.99
<b>Loci associated with abnormalities in early insulin secretion</b>											
rs10830963	MTNR1B	G/C		Beta (SE)	0.0074 (0.0054)	-0.081 (0.009)	0.046 (0.024)	-0.0079 (0.0045)	-0.0091 (0.0071)	0.0021 (0.0034)	-0.012 (0.0043)
				$P_{age+sex}$	0.17	$2.30 \times 10^{-19}$	0.057	0.077	0.20	0.55	0.0064
rs4607517	GCK	A/G		Beta (SE)	0.0026 (0.0072)	-0.048 (0.013)	0.0015 (0.033)	-0.0079 (0.0065)	-0.0053 (0.0099)	0.0029 (0.0048)	-0.023 (0.0058)
				$P_{age+sex}$	0.72	$2.22 \times 10^{-4}$	0.96	0.22	0.59	0.54	$8.13 \times 10^{-5}$
rs174550	FADS1	T/C		Beta (SE)	-0.0005 (0.0051)	-0.028 (0.0086)	0.011 (0.023)	0.0078 (0.0043)	0.005 (0.0067)	0.0048 (0.0033)	-0.0013 (0.0042)
				$P_{age+sex}$	0.93	0.0013	0.65	0.069	0.46	0.15	0.77
rs2191349	DGKB	T/G		Beta (SE)	0.0057 (0.0049)	-0.023 (0.0083)	0.0046 (0.029)	0.005 (0.0041)	0.014 (0.0064)	0.0038 (0.0032)	0.0021 (0.0041)
				$P_{age+sex}$	0.25	0.006	0.87	0.22	0.031	0.23	0.61
rs340874	PROX1	C/T		Beta (SE)	0.0069 (0.0051)	-0.02 (0.0083)	0.0062 (0.023)	-0.0042 (0.0042)	-0.0002 (0.0064)	0.0013 (0.0032)	-0.0031 (0.0041)
				$P_{age+sex}$	0.18	0.015	0.78	0.31	0.98	0.68	0.44
rs560887	G6PC2	C/T		Beta (SE)	-0.0017 (0.0073)	0.052 (0.013)	-0.045 (0.025)	0.0044 (0.0068)	-0.011 (0.0098)	-0.009 (0.0045)	-0.0052 (0.0059)
				$P_{age+sex}$	0.81	$4.98 \times 10^{-5}$	0.069	0.52	0.26	0.044	0.38
<b>Loci associated with reduced insulin sensitivity</b>											
rs780094	GCKR	C/T		Beta (SE)	0.003 (0.0054)	0.015 (0.0094)	-0.034 (0.023)	-0.017 (0.0051)	-0.032 (0.0075)	-0.011 (0.0036)	0.00 (0.0045)
				$P_{age+sex}$	0.57	0.12	0.14	0.0011	$2.89 \times 10^{-5}$	0.0033	0.99
rs35767	IGF1	G/A		Beta (SE)	0.0002 (0.0067)	-0.0061 (0.011)	-0.02 (0.03)	0.0016 (0.0054)	-0.022 (0.0084)	-0.0095 (0.0041)	-0.016 (0.0052)
				$P_{age+sex}$	0.98	0.57	0.50	0.77	0.010	0.020	0.0021
<b>No obvious effects on insulin processing, secretion or sensitivity</b>											

			Insulin processing, secretion and/or $\beta$ -cell function	Insulin secretion	Insulin sensitivity					
SNP	Nearest gene	Alleles (effect <sup>*</sup> / other)		Proinsulin <sup>†</sup> (n=17,402)	Insulinogenic index <sup>†</sup> (n=15,399)	Insulin sensitivity intravenous measures <sup>‡</sup> (n=3,195)	Stumvoll <sup>§</sup> (n=15,789)	Matsuda <sup>§</sup> (n=15,554)	Belfiore <sup>§</sup> (n=15,802)	Gutt <sup>§</sup> (n=15,999)
rs11708067	<i>ADCY5</i>	A/G	Beta (SE)	0.016 (0.0063)	-0.014 (0.011)	-0.0095 (0.027)	0.0051 (0.0054)	-0.0009 (0.0082)	-0.0031 (0.004)	-0.016 (0.0049)
			$P_{age+sex}$	0.013	0.20	0.73	0.34	0.91	0.44	0.0012
rs10885122	<i>ADRA2A</i>	G/T	Beta (SE)	-0.017 (0.0076)	-0.018 (0.013)	-0.005 (0.033)	-0.0095 (0.0062)	-0.0077 (0.0098)	-0.0011 (0.0047)	-0.0051 (0.006)
			$P_{age+sex}$	0.029	0.15	0.88	0.13	0.43	0.81	0.40
rs11605924	<i>CRY2</i>	A/C	Beta (SE)	-0.0053 (0.0049)	-0.014 (0.0083)	-0.013 (0.022)	-0.0076 (0.0041)	-0.0079 (0.0065)	-0.0027 (0.0031)	-0.0098 (0.004)
			$P_{age+sex}$	0.28	0.098	0.55	0.067	0.23	0.38	0.015
rs11920090	<i>SLC2A2</i>	T/A	Beta (SE)	-0.0112 (0.0073)	0.028 (0.012)	-0.021 (0.033)	0.0009 (0.0061)	-0.0007 (0.0096)	-0.0031 (0.0046)	-0.0095 (0.006)
			$P_{age+sex}$	0.13	0.022	0.54	0.88	0.94	0.50	0.11
rs7034200	<i>GLIS3</i>	A/C	Beta (SE)	0.018 (0.0063)	0.0008 (0.011)	0.0027 (0.028)	-0.0015 (0.0048)	0.0006 (0.0079)	-0.0043 (0.0037)	-0.0036 (0.005)
			$P_{age+sex}$	0.0050	0.94	0.92	0.75	0.94	0.24	0.48

\* Per-allele betas (standard errors) are shown at the upper lines;  $P$ -values from age- and sex-adjusted analyses are shown at the lower lines. Effect allele was defined as the 2-h glucose-raising alleles for *GIPR* rs10423928 and *VPS13C* rs17271305; the fasting insulin-raising allele for *IGF1* rs35767; and the fasting glucose-raising allele for all other SNPs.


<sup>†</sup> We used naturally log-transformed trait values for proinsulin, insulinogenic index, and the insulin sensitivity indexes.

<sup>‡</sup> Insulin sensitivity measured with standard intravenous methods (M/I derived from euglycemic hyperinsulinemic clamp(13);  $S_I$  from the frequently sampled intravenous glucose tolerance test [FSIGT] (14); and steady-state plasma glucose [SSPG] from the insulin suppression test (15)), combined after z-score transformation.


<sup>§</sup> The insulin sensitivity indices are defined in Supplementary Table 3.

Figure


A



B



C



D

